StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Tuesday morning. The brokerage issued a sell rating on the stock.

CEL-SCI Price Performance

CVM opened at $0.33 on Tuesday. CEL-SCI has a 1 year low of $0.31 and a 1 year high of $2.50. The company’s 50 day simple moving average is $0.44 and its 200 day simple moving average is $0.75. The stock has a market capitalization of $25.45 million, a PE ratio of -0.69 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CVM. Thoroughbred Financial Services LLC grew its position in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after acquiring an additional 54,900 shares during the period. Plotkin Financial Advisors LLC acquired a new position in shares of CEL-SCI in the 3rd quarter valued at about $98,000. Finally, Geode Capital Management LLC lifted its stake in shares of CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after purchasing an additional 53,879 shares in the last quarter. 12.08% of the stock is owned by hedge funds and other institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.